ImmunoPrecise Antibodies Ltd. (HYFT) Stock Analysis

ImmunoPrecise Antibodies Ltd. (HYFT) is a publicly traded company in the NONE sector. It trades at $1.97, carries a market capitalization of $81.28M. This page summarizes the public market data, fundamentals, and frequently asked questions for HYFT, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: NONE - NONE

Exchange: NASDAQ

Key Metrics

• Price: $1.97
• Market Cap: $81.28M
• EPS: $-0.10
• 52-Week High: $3.25
• 52-Week Low: $0.50

Market Sentiment

ImmunoPrecise Antibodies Ltd. currently has a Bullish sentiment score of 0.44.

About ImmunoPrecise Antibodies Ltd.

MindWalk Holdings Corp., headquartered in Austin, Texas, is a pioneering biotechnology company specializing in the development of innovative immunotherapies and antibody solutions. With a strong emphasis on precision and efficacy, the firm aims to enhance treatment options for a range of diseases through advanced research and cutting-edge technology. By leveraging its expertise in monoclonal antibodies, MindWalk is positioned to make significant contributions to the healthcare sector, address...

GNG Research Analysis

GNG Research scores ImmunoPrecise Antibodies Ltd. (HYFT) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for HYFT.

Frequently Asked Questions

Does HYFT pay dividends?

ImmunoPrecise Antibodies Ltd. (HYFT) does not currently pay a regular dividend.

What is HYFT's market cap?

ImmunoPrecise Antibodies Ltd. (HYFT) has a market capitalization of $81.28M with a current stock price of $1.97.